The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent ...

The FDA issued warning letters to 30 telehealth companies over misleading claims about compounded versions of popular ...

1. FDA. FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s. FDA News Release. March 3, 2026.

Novo Nordisk is suing a Shrewsbury doctor who sells a cheaper compounded medicine version of its popular Ozempic and Wegovy ...

NG Biotech manufactured the assays in France, with Hardy Diagnostics serving as the exclusive distributor in the US.

Novo Nordisk announced up to 50% price cuts for Ozempic and Wegovy diabetes and weight-loss drugs starting January 2027, ...

A new investigation has warned 111 chemicals were 'secretly' added to food, drinks and supplements without the FDA being ...

Add Yahoo as a preferred source to see more of our stories on Google. NG-TEST Candida auris and NG-TEST Acineto-5 LFA Cassettes. Credit: Hardy Diagnostics / PRNewswire. (Hardy Diagnostics / PRNewswire ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss drugs.

A 2026 Informational Overview of the BreezeMeds Compounded GLP-1 Telehealth Weight Loss Platform, Semaglutide and Tirzepatide ...

Examining SkinnyRx's Compounded GLP-1 Weight Loss Platform for 2026: Semaglutide and Tirzepatide Medication Formats, ...

Even Kennedy acknowledges that there isn’t robust scientific data to support the use of these peptides.